Therapy of Severe Acute Respiratory Syndrome Coronavirus 2 Pneumonia: Is There an Optimal Interleukin 6 Cutoff for Successful Tocilizumab Treatment?

Clin Infect Dis. 2021 Jul 1;73(1):e270-e271. doi: 10.1093/cid/ciaa1282.
No abstract available

Publication types

  • Letter

MeSH terms

  • Antibodies, Monoclonal, Humanized
  • COVID-19* / drug therapy
  • Humans
  • Interleukin-6
  • Pneumonia*
  • SARS-CoV-2

Substances

  • Antibodies, Monoclonal, Humanized
  • Interleukin-6
  • tocilizumab

Supplementary concepts

  • COVID-19 drug treatment